€11 billion down: how Italian pharma has been eroded
This article was originally published in Scrip
In a letter sent on 23 July to Prime Minister Mario Monti and Finance Minister Vittorio Grilli the pharma and biotech industry in Italy outlined the gloomy consequences for the country's drug market of the government actions or inactions over the past decade. And there could be worse to come, the Italian biotech industry association, Assobiotec, told Scrip.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.